Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Junko Tanizaki(Kindai University Sakai Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Hidetoshi Hayashi(Kindai University), Erina Hatashita(National Hospital Organization), Takafumi Okabe(Dana-Farber Cancer Institute), Kiyoko Kuwata(National Hospital Organization), Isamu Okamoto(Kyushu University Hospital), Hiroyasu Kaneda(Osaka City University), Haruka Yamaguchi(Nippon Dental University), Ken Takezawa(Kindai University), Kaoru Tanaka(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 156
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k